US Bioscience Report issue

Contributed to NME For profit Phase 1
Founded: Blue Bell PA United States (1987)
Status: Acquired by MedImmune (1999) → now AstraZeneca (2007)

Organization Overview

First Clinical Trial
1999
NCT00002317
First Marketed Drug
1990
altretamine (hexalen)
First NDA Approval
1990
altretamine (hexalen)
Last Known Activity
1999

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

U.S. Bioscience

Indications

Approved Indications


 

Head and Neck Neoplasms

Ovarian Neoplasms

Pneumonia, Pneumocystis

Xerostomia

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pneumonia (Phase 1)

Pneumonia, Pneumocystis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 5
  • # of Trial APIs: 5